A Phase II study of oxaliplatin in urothelial cancer (Q46501921)

22 December 2017

title

A Phase II study of oxaliplatin in urothelial cancer (English)

1 reference

22 December 2017

1 reference

2

Everett Vokes

1 reference

22 December 2017

Eric Winquist

1

1 reference

22 December 2017

Malcolm J Moore

3

1 reference

22 December 2017

L Philip Schumm

4

1 reference

22 December 2017

Kristin Hoving

5

1 reference

22 December 2017

Walter M Stadler

6

1 reference

22 December 2017

publication date

1 May 2005

1 reference

22 December 2017

published in

Urologic Oncology

1 reference

22 December 2017

volume

23

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

150-154

1 reference

22 December 2017

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

Prediction of creatinine clearance from serum creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.11.008

10.1016/J.UROLONC.2004.11.008

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

release_z2dpciuhsrfu7czjuxz3tk3fbe

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/z2dpciuhsrfu7czjuxz3tk3fbe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

22 December 2017